117 related articles for article (PubMed ID: 20840152)
1. Epstein Barr virus inhibits the stimulatory effect of TLR7/8 and TLR9 agonists but not CD40 ligand in human B lymphocytes.
Younesi V; Nikzamir H; Yousefi M; Khoshnoodi J; Arjmand M; Rabbani H; Shokri F
Microbiol Immunol; 2010 Sep; 54(9):534-41. PubMed ID: 20840152
[TBL] [Abstract][Full Text] [Related]
2. Increased expression of Toll-like receptors 7 and 9 in myasthenia gravis thymus characterized by active Epstein-Barr virus infection.
Cavalcante P; Galbardi B; Franzi S; Marcuzzo S; Barzago C; Bonanno S; Camera G; Maggi L; Kapetis D; Andreetta F; Biasiucci A; Motta T; Giardina C; Antozzi C; Baggi F; Mantegazza R; Bernasconi P
Immunobiology; 2016 Apr; 221(4):516-27. PubMed ID: 26723518
[TBL] [Abstract][Full Text] [Related]
3. Manipulation of the toll-like receptor 7 signaling pathway by Epstein-Barr virus.
Martin HJ; Lee JM; Walls D; Hayward SD
J Virol; 2007 Sep; 81(18):9748-58. PubMed ID: 17609264
[TBL] [Abstract][Full Text] [Related]
4. Innate immunity at the mucosal surface: role of toll-like receptor 3 and toll-like receptor 9 in cervical epithelial cell responses to microbial pathogens.
Andersen JM; Al-Khairy D; Ingalls RR
Biol Reprod; 2006 May; 74(5):824-31. PubMed ID: 16421230
[TBL] [Abstract][Full Text] [Related]
5. Toll-like receptor 7 cooperates with IL-4 in activated B cells through antigen receptor or CD38 and induces class switch recombination and IgG1 production.
Tsukamoto Y; Nagai Y; Kariyone A; Shibata T; Kaisho T; Akira S; Miyake K; Takatsu K
Mol Immunol; 2009 Apr; 46(7):1278-88. PubMed ID: 19157556
[TBL] [Abstract][Full Text] [Related]
6. Synergy between anti-CD40 MAb and Epstein-Barr virus in activation and transformation of human B lymphocytes.
Tsuchiyama L; Kieran J; Boyle P; Wetzel GD
Hum Antibodies; 1997; 8(1):43-7. PubMed ID: 9265505
[TBL] [Abstract][Full Text] [Related]
7. TLR7 and TLR8 agonists trigger different signaling pathways for human dendritic cell maturation.
Larangé A; Antonios D; Pallardy M; Kerdine-Römer S
J Leukoc Biol; 2009 Apr; 85(4):673-83. PubMed ID: 19164127
[TBL] [Abstract][Full Text] [Related]
8. IL-21 enhances the activity of the TLR-MyD88-STAT3 pathway but not the classical TLR-MyD88-NF-κB pathway in human B cells to boost antibody production.
Liu BS; Stoop JN; Huizinga TW; Toes RE
J Immunol; 2013 Oct; 191(8):4086-94. PubMed ID: 24043893
[TBL] [Abstract][Full Text] [Related]
9. Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity.
Krieg AM; Vollmer J
Immunol Rev; 2007 Dec; 220():251-69. PubMed ID: 17979852
[TBL] [Abstract][Full Text] [Related]
10. TLR-mediated STAT3 and ERK activation controls IL-10 secretion by human B cells.
Liu BS; Cao Y; Huizinga TW; Hafler DA; Toes RE
Eur J Immunol; 2014 Jul; 44(7):2121-9. PubMed ID: 24737107
[TBL] [Abstract][Full Text] [Related]
11. Coexpression of CD40 and CD40 ligand in Epstein-Barr virus-infected T and NK cells and their role in cell survival.
Imadome K; Shimizu N; Arai A; Miura O; Watanabe K; Nakamura H; Nonoyama S; Yamamoto K; Fujiwara S
J Infect Dis; 2005 Oct; 192(8):1340-8. PubMed ID: 16170750
[TBL] [Abstract][Full Text] [Related]
12. Toll-like receptor 7-induced naive human B-cell differentiation and immunoglobulin production.
Glaum MC; Narula S; Song D; Zheng Y; Anderson AL; Pletcher CH; Levinson AI
J Allergy Clin Immunol; 2009 Jan; 123(1):224-230.e4. PubMed ID: 18995892
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the effect of TLR7/8, TLR9 agonists and CD40 ligand on the transformation efficiency of Epstein-Barr virus in human B lymphocytes by limiting dilution assay.
Younesi V; Shirazi FG; Memarian A; Amanzadeh A; Jeddi-Tehrani M; Shokri F
Cytotechnology; 2014 Jan; 66(1):95-105. PubMed ID: 23404520
[TBL] [Abstract][Full Text] [Related]
14. Epstein Barr virus binding induces internalization of the C3d receptor: a novel immunotoxin delivery system.
Tedder TF; Goldmacher VS; Lambert JM; Schlossman SF
J Immunol; 1986 Aug; 137(4):1387-91. PubMed ID: 3016095
[TBL] [Abstract][Full Text] [Related]
15. TLR7/8 ligand, R-848, inhibits IgE synthesis by acting directly on B lymphocytes.
Shen E; Lu L; Wu C
Scand J Immunol; 2008 Jun; 67(6):560-8. PubMed ID: 18397197
[TBL] [Abstract][Full Text] [Related]
16. Comparison of human B cell activation by TLR7 and TLR9 agonists.
Hanten JA; Vasilakos JP; Riter CL; Neys L; Lipson KE; Alkan SS; Birmachu W
BMC Immunol; 2008 Jul; 9():39. PubMed ID: 18652679
[TBL] [Abstract][Full Text] [Related]
17. Negative regulation of TLR9-mediated IFN-alpha induction by a small-molecule, synthetic TLR7 ligand.
Marshall JD; Heeke DS; Gesner ML; Livingston B; Van Nest G
J Leukoc Biol; 2007 Sep; 82(3):497-508. PubMed ID: 17565046
[TBL] [Abstract][Full Text] [Related]
18. Synthetic agonists of Toll-like receptors 7, 8 and 9.
Agrawal S; Kandimalla ER
Biochem Soc Trans; 2007 Dec; 35(Pt 6):1461-7. PubMed ID: 18031246
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus infection negatively impacts the CXCR4-dependent migration of tonsillar B cells.
Ehlin-Henriksson B; Mowafi F; Klein G; Nilsson A
Immunology; 2006 Mar; 117(3):379-85. PubMed ID: 16476057
[TBL] [Abstract][Full Text] [Related]
20. CL097, a TLR7/8 ligand, inhibits TLR-4--dependent activation of IRAK-M and BCL-3 expression.
Petricevic B; Wessner B; Sachet M; Vrbanec D; Spittler A; Bergmann M
Shock; 2009 Nov; 32(5):484-90. PubMed ID: 19333135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
